Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson purchased 6,250 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were acquired at an average price of $24.95 per share, with a total value of $155,937.50. Following the purchase, the chief financial officer owned 33,054 shares in the company, valued at $824,697.30. This trade represents a 23.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Sensei Biotherapeutics Price Performance
FTH opened at $22.87 on Monday. Sensei Biotherapeutics, Inc. has a 52 week low of $6.32 and a 52 week high of $36.76. The company has a market cap of $30.65 million, a price-to-earnings ratio of -0.16 and a beta of -0.25.
Wall Street Analyst Weigh In
FTH has been the subject of several recent analyst reports. Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a research note on Friday. They issued an “outperform” rating and a $57.00 price objective for the company. Weiss Ratings started coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. HC Wainwright started coverage on Sensei Biotherapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price target on the stock. Finally, BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $58.50.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
